Clinical outcomes of gastrointestinal stromal tumor in southern Thailand

Kittima Pornsuksiri, Siripong Chewatanakornkul, Samornmas Kanngurn, Wanwisa Maneechay, Walawee Chaiyapan, Surasak Sangkhathat

AIM: To review a single institutional experience in clinical management of gastrointestinal stromal tumors (GIST) and analyze for factors determining treatment outcome.

METHODS: Clinicopathological data of patients with a diagnosis of GIST who were treated at our institute during November 2004 to September 2009 were retrospectively reviewed.

RESULTS: Ninety-nine cases were included in the analysis. Primary tumor sites were at the stomach in 44% and small bowel in 33%, respectively. Thirty-one cases already had metastasis at presentation and the most common metastatic site was the liver. Sixty-four cases (65%) were in the high-risk category. Surgical treatment was performed in 77 cases (78%), 3 of whom received upfront targeted therapy. Complete resection was achieved in 56 cases (73% of operative cases) and of whom 27 developed local recurrence or distant metastasis at a median duration of 2 years. Imatinib was given as a primary therapy in unresectable cases (25 cases) and as an adjuvant in cases with residual tumor (21 cases). Targeted therapy gave partial response in 7 cases (15%), stable disease in 27 cases (57%) and progressive disease in 13 cases (28%). Four-year overall survival was 74% (95% CI: 61%-83%). Univariate survival analysis found that low-risk tumor, gastric site, complete resection and response to imatinib were associated with better survival.

CONCLUSION: The overall outcomes of GIST can be predicted by risk-categorization. Surgery alone may not be a curative treatment for GIST. Response to targeted therapy is a crucial survival determinant in these patients.

Key words: Gastrointestinal stromal tumor; Targeted therapy; Overall survival; Progress free survival; Progressive disease

© 2012 Baishideng. All rights reserved.
INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are relatively uncommon mesenchymal neoplasms arising primarily in the wall of the stomach, small intestine, and colon, and other sites within the abdomen[1]. Although GIST comprises only 0.2% of all gastrointestinal tumors, it is the most common mesenchymal tumor, accounting for 80% of gastrointestinal tract sarcomas. Recent studies have found incidence rates of GISTs of 10-20, 7-15, and 14 cases/million per year in the United States[2], Europe[3], and Taiwan[4], respectively. The primary tumor is most commonly located in the stomach (50%-65%) or small intestine (25%-30%), however it has also been reported in the colon, esophagus and a number of extra-gastrointestinal sites[5-9].

Surgery is the mainstay treatment with a curative aim for localized GISTs without metastasis. Previous studies have found five-year disease free survival in primary GISTs in whom complete surgical resection could be achieved to be 65%[8,9], although another study found recurrent disease in a number of cases after complete surgical resection at a median time of 20 mo[9]. In primarily unresectable or metastatic disease, the current first line treatment is a tyrosine kinase inhibitor, imatinib mesylate. Such molecular targeted therapy gives a varying response rate depending on the tumor location, histological risk stratification and mutation status of the receptor tyrosine kinase KIT. In general, symptomatic GIST cases who were in the high risk group have shown poorer disease free survival rates even when complete surgical resection could be achieved[10-12] Other than histopathological criteria, risk determinants for disease specific survival include non-gastric primary location, macroscopic residual tumor and tumor rupture. In unresectable cases, various studies have found that factors determining response were primarily biological characteristics, including a high mitotic index and KIT mutation status[10,11,14].

This study aimed to review the clinical presentations, pathological characteristics and treatment outcomes of GIST cases in a university hospital setting in Southern Thailand, analyzed for factors effecting treatment outcomes.

MATERIALS AND METHODS

The study was approved by the Institutional Ethic Committee of the Faculty of Medicine, Prince of Songkla University. A list of patients with the pathological diagnosis of GIST during November 2004 to September 2009 was obtained from the Department of Pathology and the Tumor Registry Unit of our institution, Songklanagarind Hospital. Details on sociodemographic and clinical data, pathological and laboratory findings, and treatment were retrieved from the hospital information system. A diagnosis of GIST was based on a histopathological appearance that was compatible with GIST (spindle or epithelioid cell type) and was confirmed by positive immunohistochemical staining for CD117. Patients who were referred to our institute after a diagnosis was made were included only if the pathological slides were available for review. Patients without adequate follow-up were excluded from this review.

The morphological characteristics of the tumors were evaluated according to the risk stratification criteria of the National Institutes of Health (NIH) consensus (Fletcher’s criteria 2002)[10], which classifies GISTs into very low, low, intermediate, and high risk categories. Our treatment usually began with surgical removal of the tumor if possible. In cases with unresectable tumor or distant metastasis, treatment began with a daily dose of 400 milligrams of imatinib, a tyrosine kinase inhibitor. Response to the treatment was evaluated and assessed by a radiologist, beginning at 12 mo after treatment initiation, based on the Response Evaluation Criteria In Solid Tumors (RECIST) method[11]. Long-term treatment outcomes included overall survival (OS) and progress free survival (PFS) with recurrence, progressive disease and death set as sensors for the PFS analysis.

The mutation status of the tumors was analyzed in cases in which a specimen was available. For analysis, tumor DNA was extracted from formalin-fixed paraffin embedded tissue using a DNeasy Blood and Tissue Kit (Qiagen). The mutation study covered exons 9 and 11 of KIT. The studies used polymerase chain reaction and direct nucleotide sequencing method.

Descriptive statistics were used to describe the base line characteristics and clinical information of each patient. Univariate survival analysis used the Log-rank test and a stepwise Cox proportional hazard analysis was used for multivariate survival analysis. The statistical significance of each variable was tested by a log-likelihood ratio of successive models at a $P$ value < 0.05. All analysis was done using the Stata version 6.0 program (Stata Corporation, TX).

RESULTS

From November 2004 to September 2009, 100 patients were diagnosed with GIST. One patient was excluded due to being lost to follow up before receiving any treatment, leaving 99 cases in the analysis. Patients who were referred after initial diagnosis accounted for 51% of the total. Gender distribution was 55 male: 44 female or 1.25:1. The median age at diagnosis was 58 years (range 10-82 years). The only case of pediatric GIST was a girl who presented at the age of 10 years. Almost all patients (87%) were symptomatic and about half (57%) presented with an abdominal mass. Twenty-six patients (26%) came with gastrointestinal bleeding, 2 had gut obstruction and 2 had intestinal perforation.

The most common primary tumor sites were the stomach (43 cases, 44%) and small bowel (33 cases, 33%). The other sites were the rectum (5 cases), omentum (2 cases), retroperitoneal (3 cases) and unknown primary (13 cases). Thirty-one cases already had metastasis at presentation and the most common metastatic site was the liver.
When the NIH risk criteria was used to categorize the cases, 65% of the patients were in the high risk group, with 17%, 12% and 6% in the intermediate, low and very low risk groups, respectively. On histopathology, 98% of cases were positive for CD117 immunohistochemistry, positive staining for CD34 was 79%, smooth muscle actin 30%, S100 24% and desmin 9%. Mutations of KIT were studied in 35 cases whose specimens were available. The study detected KIT mutations in 19 cases; 17 in exon11 and 2 in exon9.

**Surgical treatment**

The seventy-seven cases who underwent surgical treatment included 74 cases who had primary surgery and 3 cases who received upfront tyrosine kinase inhibitor therapy prior to their operation (Figure 1). Fifty-six cases in this group (73% of operative cases) achieved complete resection. About half of these 56 (29 cases) were in the high risk group according to the NIH risk classification. Seven of the patients who had a complete resection later developed local recurrence, and 14 distant metastases. Twenty of these 21 cases were in the high risk category and the median time to recurrence was 23.3 mo. In the 25 unresectable cases, 16 cases (64%) originally presented with metastasis, all of which were categorized as high risk according to the NIH risk classification. In the 9 of these cases without metastasis, the main reason for unresectability was structure involvement.

We achieved complete resection in the majority of gastric GIST cases (70%), the complete resection rate was 46% in extra-gastric tumors (Table 1).

**Response to tyrosine kinase inhibitors**

Tyrosine kinase inhibitor therapy was given to our patients when they had an unresectable tumor, residual disease, or recurrence after primary surgical resection. According to the RECIST, of the 47 patients who received tyrosine kinase inhibitor therapy, 7 cases (15%) had partial response, 27 cases (57%) had stable disease, and 13 cases (28%) had progressive disease. Of the 3 cases in which surgical exploration was performed after targeted therapy and the radiologic diagnosis scored stable disease or partial response, one achieved a complete pathological response (Figure 2). Adverse reactions were recorded in 18 cases (38%). The three most common adverse reactions were edema (6 cases, 13%), anemia (5 cases, 11%) and skin rash (3 cases, 6%).

When the primary tumor site was considered, 4 cases (31%) of gastric GIST achieved a partial response, which was significantly higher than in the other sites (P = 0.047) (Table 2).

**Survival analysis**

Until the preparation of this manuscript in September 2011, the mean follow-up period was 49 mo. The four-year overall OS and PFS rates (Figure 3) were 74% (95% CI: 61%-83%) and 72% (95% CI: 59%-82%), respectively.

On univariate analysis, presence of liver metastasis, presence of residual disease or unresectability, high risk disease, non-gastric primary site, presence of liver metastasis and unresponsiveness to targeted therapy were factors that were significantly associated with poorer OS. On multivariate analysis, the NIH risk category was the only factor that most fit the Cox regression model at the hazard ratio of 6.12 (95% CI: 61%-83%) and 72% (95% CI: 59%-82%), respectively.

DISCUSSION

It has only been since around the year 2000 that the term GIST began to appear in pathological reports in our institute. The diagnosis became more common in the following years, possibly due to increasing awareness of this diagnosis of both the pathologists and the clinicians. In general, the tumor is defined as a mesenchymal neoplasm arising in the gastrointestinal tract and expressing KIT (CD117)[16]. The mainstay treatment for a GIST is surgical removal. The five-year survival rate after complete surgical resection was reported at 48%-79%[17]. In situations where complete resection is not possible, tyro-

---

**Table 1: Resectability of gastrointestinal stromal tumor according to primary tumor sites n (%)**

<table>
<thead>
<tr>
<th>Primary sites</th>
<th>No. of cases</th>
<th>Complete resection</th>
<th>Residual disease</th>
<th>Unresectable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>43</td>
<td>30 (70)</td>
<td>9 (20)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Small bowel</td>
<td>33</td>
<td>20 (61)</td>
<td>6 (18)</td>
<td>7 (21)</td>
</tr>
<tr>
<td>Rectum</td>
<td>5</td>
<td>2 (40)</td>
<td>1 (20)</td>
<td>2 (40)</td>
</tr>
<tr>
<td>Extra-gastrointestinal</td>
<td>18</td>
<td>4 (22)</td>
<td>5 (28)</td>
<td>9 (50)</td>
</tr>
</tbody>
</table>

---

**Figure 1: Categorization of 99 cases of gastrointestinal intestinal tumor according to their resectability. GIST: Gastrointestinal stromal tumor; N: Number.**
sine kinase targeted therapy is the current treatment of choice.

In our study, a majority of our patients were symptomatic cases that belonged to the high risk category. At presentation, 25% of the cases were considered unresectable, either due to anatomical difficulty or presence of distant metastasis. Surgery was performed in 78% and complete resection was achieved in 73% in cases who underwent surgical exploration. However, we found that 48% of the patients who achieved complete tumor removal developed local recurrence or distant metastasis at a median duration of 2 years. This figure was consistent with previous studies that also experienced a medium-term recurrence after the surgical treatment alone\[18-20\].

Table 2  Response to targeted therapy according to site of primary tumor n (%)  

<table>
<thead>
<tr>
<th>Group</th>
<th>PR 1</th>
<th>SD</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>All 47 cases</td>
<td>7 (15)</td>
<td>27 (57)</td>
<td>13 (28)</td>
</tr>
<tr>
<td>Stomach (13 cases)</td>
<td>4 (31)</td>
<td>7 (54)</td>
<td>2 (15)</td>
</tr>
<tr>
<td>Small bowel (19 cases)</td>
<td>1 (5)</td>
<td>10 (53)</td>
<td>8 (42)</td>
</tr>
<tr>
<td>Rectum (2 cases)</td>
<td>-</td>
<td>2 (100)</td>
<td>-</td>
</tr>
<tr>
<td>Extra-gastrointestinal (13 cases)</td>
<td>2 (15)</td>
<td>8 (62)</td>
<td>3 (23)</td>
</tr>
</tbody>
</table>

1Response as evaluated by the response evaluation criteria in solid tumors method; 2One case in this group had complete histopathological response. SD: Stable disease; PD: Progressive disease; PR: Partial response.

Figure 2  Abdominal computerized tomography and histopathological pictures of a 68-year-old male patient who presented with abdominal mass. A: Computerized tomography (CT) shows a large enhancing solid mass (T), measuring 11.2 cm × 11.9 cm × 10.7 cm, occupying the left upper quadrant between the stomach and the spleen. A liver nodule is also visible in segment IV; B: Forty months following the beginning of imatinib therapy, a follow-up CT showed partial tumor response; C, D: Image-guided tissue biopsy revealed a spindle cell tumor (arrows) that marked CD117. The mitotic cell count was 2 cells/50 high power fields; E, F: Following an en bloc resection including a total removal of the stomach together with the spleen and a wedge resection of hepatic metastasis, the pathological tissue showed only a stromal hyalinization and dystrophic calcification with a scanty number of differentiated spindle cells that marked S-100, but not CD117.
of postoperative adjuvant treatment in the high risk patient. Two recent studies have suggested that adjuvant imatinib therapy may improve RFS after the resection of a primary gastrointestinal stromal tumor\[21-23\], although these studies had only a limited follow-up duration, thus the findings are still not confirmed.

The GIST is not a chemosensitive tumor. Nevertheless, small molecule targeting the specific tyrosine kinase is an effective adjuvant treatment and is a prototype of targeted therapy in human neoplasms. Imatinib mesylate is a compound known to be active against BCR-ABL, KIT receptors and platelet-derived growth factor receptor-\(\alpha\)[23]. Imatinib clearly has a role in unresectable GISTs and also resectable GISTs with residual disease after surgery. A number of studies examining the efficacy of imatinib in advanced GISTs found that it gave 5% complete response, 45%-65% partial response and 18%-32% stable disease\[24-26\]. The 15% partial response and 56% stable disease rates in our patients were relatively low. However, the 4-year OS of 74% in our patients was compatible with other major studies in the post-imatinib era\[19,27,28\]. We had 3 patients in whom upfront imatinib converted the tumor from unresectable to removable. As mentioned earlier, one of these cases had pathologically complete remission and 2 cases had tumor shrinkage, to an extent that then allowed their complete removal, suggesting a positive role for this drug in preoperative down-staging of GISTs. In addition, our study

![Kaplan-Meier survival probability curves](image)

**Figure 3** Kaplan-Meier survival probability curves. Kaplan-Meier survival probability curves showing overall survival (OS) (A) progress free survival (PFS) (B), significant difference in the recurrent free survival (RFS) after surgery in primary resectable cases, comparing between the cases in the high risk group according to the National Institute of Health risk categorization, and the cases in the other risk groups (C) and significant difference in the OS (D).

<table>
<thead>
<tr>
<th>Risk Categorization</th>
<th>Four-year OS (%)</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS (99 cases)</td>
<td>72.4</td>
<td></td>
</tr>
<tr>
<td>Primary tumor site</td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>Stomach</td>
<td>86.5</td>
<td></td>
</tr>
<tr>
<td>Non-stomach</td>
<td>64.5</td>
<td></td>
</tr>
<tr>
<td>Risk category(^1)</td>
<td></td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Non-high risk (35 cases)</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>High risk (64 cases)</td>
<td>60.9</td>
<td></td>
</tr>
<tr>
<td>Liver metastasis at diagnosis</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>Absent (72 cases)</td>
<td>86.3</td>
<td></td>
</tr>
<tr>
<td>Present (27 cases)</td>
<td>44.6</td>
<td></td>
</tr>
<tr>
<td>Residual disease after surgery</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>Absent (56 cases)</td>
<td>84.1</td>
<td></td>
</tr>
<tr>
<td>Present (21 cases)</td>
<td>61.5</td>
<td></td>
</tr>
<tr>
<td>Response to targeted therapy</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>CR + PR (8 cases)</td>
<td>88.9</td>
<td></td>
</tr>
<tr>
<td>SD + PD (40 cases)</td>
<td>64.2</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\)Risk categorization according to the United States National Institute of Health consensus 2002. OS: Overall survival; SD: Stable disease; PD: Progressive disease; CR: Complete response; PR: Partial response.

Table 3 Univariate survival analysis of factors associated with survival in 99 cases of gastrointestinal stromal tumors
found that gastric GISTs responded to the treatment better than other sites, which may explain the better prognosis of GISTs in this location\(^a\). A recent multi-institutional trial suggested that extension of imatinib treatment duration to 36 mo significantly improved RFS for operable GISTs\(^b\).

On survival analysis, the study found associations between certain clinical parameters and survival, including gastric site, risk categorization and treatment factors. An excellent outcome could be expected if complete resection could be achieved. Up to 95% 3-year OS was observed in cases with complete tumor removal. In cases that could not have their tumor removed in the first place, disease control depended solely on the response to targeted therapy. Unresectable cases which imatinib failed to control the tumor growth had an average 3-year OS of less than 60%, compared to 80% in those who achieved at least stable disease status. Although the resectability and targeted therapy response were crucial outcome determinants, analysis of the whole series showed that the NIH risk categorization was an independent factor that predicted survival probability in our patients. On average, patients who were not in the high-risk group had more than 90% survival probability. This could be partly at least explained by noting that high risk patients were less likely to have a complete tumor removal, as tumor size is one parameter that determines risk in the NIH risk consensus.

In conclusion, our study examined the treatment outcomes of GISTs over a 5-year period in a teaching hospital in southern Thailand. The study found that the outcomes were mainly determined by tumor resectability and response to targeted therapy and that NIH risk categorization could predict the overall prognosis.

ACKNOWLEDGMENTS
The authors thank the Cancer Registry Unit, Songklanagarind Hospital for the survival status data. Dave Patterson edited English language in the manuscripts.

REFERENCES
11. Rutkowski P, Deb vie-Rychter M, Nowecki ZL, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygot J, Nyc kowski P, Krawczyk M, Ruka W. Different factors are responsible for predicting relapses after primary tumors resection and complete tumor removal. In cases that could not have their tumor removed in the first place, disease control depended solely on the response to targeted therapy. Although the resectability and targeted therapy response were crucial outcome determinants, analysis of the whole series showed that the NIH risk categorization was an independent factor that predicted survival probability in our patients.

Termiology
GIST is one of the most common mesenchymal tumors of the gastrointestinal tract (1%-3% of all gastrointestinal malignancies). They are defined as tumors whose behavior is driven by mutations in the Kit gene or PDGFRα gene, and may or may not stain positively for Kit.

Peer review
This is a retrospective study of GISTs in a single institution in Thailand. Despite the lack of novelty, the manuscript was scientifically well written. It is important to share clinical data on GISTs worldwide and to clarify nation-specific trends of this rare disease. Thus, the reviewer thinks this case series study from Thailand is valuable and potentially worth publishing.

COMMENTS
Background
Gastrointestinal stromal tumors (GISTs) are relatively uncommon mesenchymal neoplasms arising primarily in the wall of the stomach, small intestine, and colon, and other sites within the abdomen. Surgery is the mainstay treatment with a curative aim for localized GISTs without metastasis. In primarily unresectable or metastatic disease, the current first line treatment is a tyrosine kinase inhibitor, imatinib mesylate. Such molecular targeted therapy gives a varying response rate depending on the tumor location, histological risk stratification and mutation status of the receptor tyrosine kinase Kit.

Research frontiers
This study aimed to review the clinical presentations, pathological characteristics and treatment outcomes of GIST cases in a university hospital setting in Southern Thailand, analyzed for factors effecting treatment outcomes.

Applications
On survival analysis, the study found associations between certain clinical parameters and survival, including gastric site, risk categorization and treatment factors. An excellent outcome could be expected if complete resection could be achieved. Up to 95% 3-year overall survival (OS) was observed in cases with...